Browse by category

Rani Therapeutics has initiated a Phase 1 clinical trial to evaluate the safety, tolerability, bioavailability and pharmacokinetics and pharmacodynamics of single and multiple doses of RT-114, an orally administered RaniPill capsule containing a GLP-1/GLP-2 dual agonist, PG-102, for the treatment of obesity. RaniPill PG-102 is a fc-fusion protein conjugated GLP-1/GLP-2 dual agonist in development by ProGen, which recently announced preclinical and clinical data, at the 2025 E

Rani Therapeutics has announced pharmacokinetic and pharmacodynamic data from a preclinical study evaluating RT-114, a GLP-1/GLP-2 dual...

Rani Therapeutics has revealed new pharmacokinetic (PK) and pharmacodynamic (PD) data from a preclinical study evaluating the oral...